Impact of recommendations on the initial therapy of Parkinson’s disease: A population-based study in France

Fayard, Claudine; Bonaventure, Audrey; Bénatru, Isabelle; Roze, Emmanuel; Dumurgier, Julien; Moisan, Frédéric; Soumaré, Aïcha; Houssinot, Jean; Dupupet, Jean-Luc; Mazurie, Jean-Louis; Balaboi, Irina; Houeto, Jean‐Luc; Krim, E.; Ranoux, Daniéle; Goldberg, Marcel; Imbernon, Ellen; Moreau, Thibault; Giroud, Maurice; Tzourio, Christophe; Elbaz, Alexis

doi:10.1016/j.parkreldis.2011.04.020

Cited by 15 publications

(21 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among incident cases of PD in the United States, l ‐dopa is prescribed as initial therapy in greater than 70% of individuals . In population‐based studies in Italy and France, the results are similar; and, in a sample of hospitalized patients with PD, 85% are treated with l ‐dopa …”

Section: Discussionmentioning

confidence: 96%

Prevalence and Correlates of Anti‐Parkinson Drug Use in a Nationally Representative Sample

Dahodwala

Willis

et al. 2016

Movement Disord Clin Pract

View full text Add to dashboard Cite

Background Although numerous prescription drugs are available to treat Parkinson's disease (PD), little is known about national use in clinical practice and which factors may influence variability in care. The objectives of this study were to describe the prevalence of anti‐Parkinson drug use among Medicare beneficiaries with PD and to identify demographic and clinical factors associated with drug use. Methods This retrospective study was based on a random sample of annual 5% Medicare Part A and B claims linked with Medicare Part D drug files from 2007 through 2010. The study sample included fee‐for‐service Medicare beneficiaries with continuous stand‐alone Part D enrollment who had been diagnosed with PD in the given year. First, any PD drug use and drug use by class (levodopa, dopamine agonist, anticholinerigc, monoamine oxidase B inhibitors, catechol‐O‐methyltransferase inhibitors, and amantadine) were described. Using generalized estimating equation regressions, patient and provider characteristics associated with anti‐Parkinson drug use and choice were examined. Results Over 81% of patients with PD were treated with anti‐Parkinson drugs, and this proportion was stable over the 4 years of the study. The majority were treated with levodopa (90%); followed by dopamine agonists (29–31%); then monoamine oxidase B inhibitors, anticholinergics, amantadine, and catechol‐O‐methyltransferase inhibitors (all between 5% and 11%). Holding all else equal, patients who were not seen by a neurologist (odds ratio, 0.41; 95% confidence interval, 0.38–0.44; P < 0.001) and African‐American patients (odds ratio, 0.80; 95% confidence interval, 0.69–0.93; P = 0.003) were significantly less likely to be treated. Conclusions Among a national sample of Medicare beneficiaries with PD, the majority received anti‐Parkinson drugs. However, there was relative under‐treatment of African‐Americans and patients who were not seen by a neurologist for care.

show abstract

Section: Discussionmentioning

confidence: 96%

Prevalence and Correlates of Anti‐Parkinson Drug Use in a Nationally Representative Sample

Dahodwala

Willis

et al. 2016

Movement Disord Clin Pract

View full text Add to dashboard Cite

show abstract

“…A population-based case-control study was performed within a health insurance system ( Mutualité Sociale Agricole , MSA). Patients (18–80 years) from five French districts who were treated for PD were included (2006–2007) [17] . They were examined by neurologists and PD was diagnosed using standard criteria [18] .…”

Section: Methodsmentioning

confidence: 99%

Lack of Replication of the GRIN2A-by-Coffee Interaction in Parkinson Disease

et al. 2014

Self Cite

View full text Add to dashboard Cite

“…Patients (18–75 years) applying for free coverage (February 1998 through August 1999) were included in the Terre study (from 62 of 96 districts in metropolitan France) 9–11. Patients (18–80 years) from 5 French districts who benefited from free coverage or bought antiparkinsonian drugs were included in the Partage study (2006–2007) 12. Patients were examined by neurologists: parkinsonism was defined by ≥2 cardinal signs; PD was defined by parkinsonism after exclusion of other causes 13.…”

Section: Methodsmentioning

confidence: 99%

Association between Parkinson's disease and the HLA‐DRB1 locus

Ahmed

Tamouza

Delord³

et al. 2012

Movement Disorders

Self Cite

106

View full text Add to dashboard Cite

Two genome-wide association studies (GWASs) recently highlighted the HLA-DRA and HLA-DRB5 genes as associated with Parkinson disease (PD). However, because HLA-DRA displays a low level of polymorphisms and HLA-DRB5 is only present in approximately 20% of the population, these findings are difficult to interpret. Our aims were: (1) to replicate and investigate in greater detail the association between PD and the HLA-DR region; (2) to identify PD-associated HLA alleles; and (3) to perform a meta-analysis of our top finding. As part of 2 French population-based case-control studies of PD including highly ethnically homogeneous participants, we investigated the association between PD and 51 Single-nucleotide polymorphisms (SNPs) in the HLA-DR region. HLA-DRB1 alleles were imputed using the HLA(*) IMP software. HLA typing was performed in a subsample of the participants. We performed a meta-analysis of our top finding based on 4 GWAS data sets. Among 499 cases and 1123 controls, after correction for multiple testing, we found an association with rs660895 (OR/minor allele, 0.70; 95% CI, 0.57-0.87) within the HLA-DRB1 gene, which encodes the most polymorphic HLA-DR chain (DRβ). A meta-analysis (7996 cases, 36455 controls) confirmed this association (OR, 0.86; 95% CI, 0.82-0.91; P < .0001). SNP-based imputation of HLA alleles showed an inverse association between PD and the HLA-DRB1(*) 04 allele. We replicated an association between PD and the HLA-DR region and provided further insight into the loci and alleles involved. The highly polymorphic HLA-DRB1 locus contains rs660895, which represents a more legitimate candidate than previous ones. Our finding is in agreement with the hypothesis of an immune component in PD pathophysiology.

show abstract

Impact of recommendations on the initial therapy of Parkinson’s disease: A population-based study in France

Cited by 15 publications

References 13 publications

Prevalence and Correlates of Anti‐Parkinson Drug Use in a Nationally Representative Sample

Prevalence and Correlates of Anti‐Parkinson Drug Use in a Nationally Representative Sample

Lack of Replication of the GRIN2A-by-Coffee Interaction in Parkinson Disease

Association between Parkinson's disease and the HLA‐DRB1 locus

Contact Info

Product

Resources

About